RenovoRx (RNXT) EBT Margin (2025 - 2026)

RenovoRx (RNXT) posted EBT Margin of 618.47% for Q1 2026, up 58.21% sequentially from 1479.87% in Q4 2025, and up 112011.0% YoY from N/an in Q1 2025.

RenovoRx (RNXT) EBT Margin (2025 - 2026) Analysis & Trends

RenovoRx has reported EBT Margin for 2 years, with the latest figure at 618.47% in Q1 2026.

Quarterly EBT Margin rose 112011.0% year-over-year to 618.47% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 989.39% (changed N/A YoY) and the FY2025 annual result came in at 2877.11%, up 6166707.0% from the prior year.
EBT Margin grew to 618.47% in Q1 2026 per RNXT's latest filing, from 1479.87% in the prior quarter.
Over five years, EBT Margin peaked at 618.47% in Q1 2026 and troughed at 1738.58% in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	139.25 Bn	131.40 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	86.04 Bn	78.05 Bn	3.93 Bn	35.61%
3	Argenx Se	65.43 Bn	60.25 Bn	1.37 Bn	35.71%
4	Moderna	58.26 Bn	53.13 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	42.10 Bn	37.00 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	31.61 Bn	28.31 Bn	992.69 Mn	13.77%
7	BioNTech SE	28.03 Bn	9.63 Bn	668.28 Mn	-25.06%
8	Insmed	27.49 Bn	26.33 Bn	358.27 Mn	-2.67%
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	12.09%
10	RenovoRx	61.32 Mn	61.32 Mn	766,000.00	-358.53%

Download Data